BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that members of the Company’s management team will present a corporate overview at two upcoming investor conferences:
2011 RBC Capital Markets Healthcare Conference
Thursday, March 3, at 1:30 PM ET
New York, NY
ROTH 23rd Annual Growth Stock Conference
Monday, March 14, at 10:30 AM PT
Dana Point, CA
The presentations will be webcast live and may be accessed by visiting the Micromet website at www.micromet.com. A replay of the webcasts will also be available on the Company's website.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.
Director, Corporate Communications
KEYWORDS: United States North America California Maryland New York
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical